GLYXAMBI
Total Payments
$193,688
Transactions
3,666
Doctors
2,005
Companies
9
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,196 | 67 | 58 |
| 2023 | $550.74 | 29 | 29 |
| 2022 | $38.69 | 3 | 3 |
| 2021 | $9,902 | 49 | 47 |
| 2020 | $20,706 | 537 | 435 |
| 2019 | $74,245 | 956 | 568 |
| 2018 | $41,797 | 745 | 470 |
| 2017 | $45,252 | 1,280 | 733 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $73,170 | 122 | 37.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,815 | 6 | 33.5% |
| Food and Beverage | $42,946 | 3,353 | 22.2% |
| Travel and Lodging | $10,159 | 4 | 5.2% |
| Education | $2,098 | 180 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $500.00 | 1 | 0.3% |
Top Doctors Receiving Payments for GLYXAMBI — Page 81
Ad
Manufacturing Companies
- Boehringer Ingelheim International GmbH $59,600
- Boehringer Ingelheim (Phil.) Inc. $51,705
- Boehringer Ingelheim Pharmaceuticals, Inc. $25,577
- Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda. $20,094
- Lilly USA, LLC $19,944
- Boehringer Ingelheim MENA (Scientific Office) FZ-LLC $8,235
- Nippon Boehringer Ingelheim Co., Ltd. $4,510
- Boehringer Ingelheim India Pvt. Ltd. $4,000
- Eli Lilly Export S.A. Puerto Rico Branch $22.37
Product Information
- Type Drug
- Total Payments $193,688
- Total Doctors 2,005
- Transactions 3,666
About GLYXAMBI
GLYXAMBI is a drug associated with $193,688 in payments to 2,005 healthcare providers, recorded across 3,666 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim International GmbH.
Payment data is available from 2017 to 2024. In 2024, $1,196 was paid across 67 transactions to 58 doctors.
The most common payment nature for GLYXAMBI is "Consulting Fee" ($73,170, 37.8% of total).